Endogenous cannabinoid and opioid systems and their role in nicotine addiction
- PMID: 20017727
- DOI: 10.2174/138945010790980358
Endogenous cannabinoid and opioid systems and their role in nicotine addiction
Abstract
Nicotine addiction is a complex behavioural alteration, in which many neuronal pathways and neurotransmitters are involved. For a long time, dopamine has been considered one of the most important neurotransmitters in mediating the rewarding effects of nicotine. In addition, a great amount of research suggests that the endogenous cannabinoid and opioid systems play an overall modulatory effect on the reward circuitry and participate in the addictive properties of most of the prototypical drugs of abuse. This review focuses on recent behavioural and biochemical data involving these systems in the different processes that contribute to tobacco addiction. A possible role for the endogenous cannabinoid and opioid systems in the rewarding properties of nicotine as well as in the development of nicotine physical dependence and relapse to nicotine-seeking behaviour will be examined. According to preclinical studies, clinical trials suggest that the manipulation of these systems with cannabinoid or opioid antagonists could be a potential therapeutical strategy for treating nicotine addiction.
Similar articles
-
The endogenous cannabinoid system modulates nicotine reward and dependence.J Pharmacol Exp Ther. 2008 Aug;326(2):483-92. doi: 10.1124/jpet.108.138321. Epub 2008 May 1. J Pharmacol Exp Ther. 2008. PMID: 18451315 Free PMC article.
-
Endogenous opioid system: a promising target for future smoking cessation medications.Psychopharmacology (Berl). 2017 May;234(9-10):1371-1394. doi: 10.1007/s00213-017-4582-0. Epub 2017 Mar 11. Psychopharmacology (Berl). 2017. PMID: 28285326 Review.
-
Cannabinoid-opioid interactions in drug discrimination and self-administration: effect of maternal, postnatal, adolescent and adult exposure to the drugs.Curr Drug Targets. 2010 Apr;11(4):450-61. doi: 10.2174/138945010790980295. Curr Drug Targets. 2010. PMID: 20017729 Review.
-
Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors.Curr Drug Targets. 2010 Apr;11(4):406-28. doi: 10.2174/138945010790980312. Curr Drug Targets. 2010. PMID: 20196742 Review.
-
New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence.Int J Mol Sci. 2021 Dec 10;22(24):13316. doi: 10.3390/ijms222413316. Int J Mol Sci. 2021. PMID: 34948106 Free PMC article. Review.
Cited by
-
Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase.Chem Commun (Camb). 2014 May 18;50(38):4904-7. doi: 10.1039/c4cc00967c. Chem Commun (Camb). 2014. PMID: 24691497 Free PMC article.
-
Mechanistic insights into nicotine withdrawal.Biochem Pharmacol. 2011 Oct 15;82(8):996-1007. doi: 10.1016/j.bcp.2011.07.075. Epub 2011 Jul 20. Biochem Pharmacol. 2011. PMID: 21782803 Free PMC article. Review.
-
Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment.Life (Basel). 2022 Dec 15;12(12):2117. doi: 10.3390/life12122117. Life (Basel). 2022. PMID: 36556483 Free PMC article. Review.
-
Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.Psychopharmacology (Berl). 2016 May;233(10):1765-77. doi: 10.1007/s00213-015-4196-3. Epub 2016 Jan 4. Psychopharmacology (Berl). 2016. PMID: 26728894 Review.
-
Tobacco addiction and the dysregulation of brain stress systems.Neurosci Biobehav Rev. 2012 May;36(5):1418-41. doi: 10.1016/j.neubiorev.2012.02.015. Epub 2012 Mar 3. Neurosci Biobehav Rev. 2012. PMID: 22405889 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources